Literature DB >> 17222544

Diagnosis and management of pulmonary hypertension over the past 100 years.

S A van Wolferen1, K Grünberg, A Vonk Noordegraaf.   

Abstract

Pulmonary hypertension is a rare disease with a poor prognosis. It was first described in the late 19th century as a clinical-pathological syndrome characterised by obstruction of the small pulmonary arteries and right ventricular hypertrophy in patients presenting with severe dyspnoea and cyanosis. After the development of right heart catheterisation in the second half of the 20th century, it was found that many diseases could cause pulmonary hypertension, which is now recognised to be high blood pressure in the arteries that supply the lungs. In the 1960s, an epidemic of pulmonary hypertension caused by appetite suppressants initiated a systematic collection of information on pulmonary hypertension, leading to the first international classification of pulmonary hypertension. Increased understanding of the pathogenesis of the various forms of pulmonary hypertension has led to novel treatments and holds promise for the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222544     DOI: 10.1016/j.rmed.2006.11.022

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

1.  Progress in the understanding and management of pulmonary arterial hypertension.

Authors:  A M Chakrabarti; J A Mitchell; S J Wort
Journal:  Glob Cardiol Sci Pract       Date:  2015-04-04

Review 2.  An Overview of miRNAs Involved in PASMC Phenotypic Switching in Pulmonary Hypertension.

Authors:  Weifang Zhang; Zeying Tao; Fei Xu; Qian Diao; Juan Li; Lu Zhou; Yaxin Miao; Shanshan Xie; Jinjin Wan; Ruilai Xu
Journal:  Biomed Res Int       Date:  2021-10-07       Impact factor: 3.411

Review 3.  The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.

Authors:  Jenny L Hewes; Ji Young Lee; Karen A Fagan; Natalie N Bauer
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.